Nisa Investment Advisors LLC raised its stake in Celgene Corp. (NASDAQ:CELG) by 9.2% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 247,313 shares of the biopharmaceutical company’s stock after buying an additional 20,900 shares during the period. Nisa Investment Advisors LLC’s holdings in Celgene Corp. were worth $25,852,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in Celgene Corp. by 0.8% in the second quarter. Vanguard Group Inc. now owns 47,833,717 shares of the biopharmaceutical company’s stock valued at $4,717,840,000 after buying an additional 395,600 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in Celgene Corp. by 0.6% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 20,241,642 shares of the biopharmaceutical company’s stock valued at $1,996,433,000 after buying an additional 117,543 shares in the last quarter. BlackRock Fund Advisors boosted its position in Celgene Corp. by 0.3% in the second quarter. BlackRock Fund Advisors now owns 15,066,831 shares of the biopharmaceutical company’s stock valued at $1,486,042,000 after buying an additional 48,168 shares in the last quarter. Carmignac Gestion boosted its position in Celgene Corp. by 28.1% in the second quarter. Carmignac Gestion now owns 9,708,359 shares of the biopharmaceutical company’s stock valued at $957,535,000 after buying an additional 2,127,659 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in Celgene Corp. by 0.3% in the second quarter. TIAA CREF Investment Management LLC now owns 8,306,276 shares of the biopharmaceutical company’s stock valued at $819,248,000 after buying an additional 22,264 shares in the last quarter. 76.43% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Celgene Corp. (NASDAQ:CELG)

Shares of Celgene Corp. (NASDAQ:CELG) traded down 1.15% during midday trading on Wednesday, reaching $120.72. 1,041,746 shares of the company traded hands. Celgene Corp. has a 12-month low of $93.05 and a 12-month high of $127.00. The company has a 50-day moving average of $108.88 and a 200 day moving average of $106.73. The firm has a market capitalization of $93.58 billion, a PE ratio of 45.85 and a beta of 1.71.

Celgene Corp. (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.10. Celgene Corp. had a net margin of 19.71% and a return on equity of 70.48%. The firm had revenue of $2.98 billion for the quarter, compared to analyst estimates of $2.84 billion. During the same quarter in the prior year, the business earned $1.23 earnings per share. The business’s quarterly revenue was up 27.8% compared to the same quarter last year. On average, equities analysts forecast that Celgene Corp. will post $5.92 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2016/11/30/celgene-corp-celg-shares-bought-by-nisa-investment-advisors-llc.html.

CELG has been the topic of several research reports. Vetr lowered Celgene Corp. from a “strong-buy” rating to a “buy” rating and set a $115.50 price target on the stock. in a research note on Monday, October 31st. BTIG Research restated a “buy” rating and set a $138.00 price target on shares of Celgene Corp. in a research note on Sunday, August 21st. BMO Capital Markets restated an “outperform” rating and set a $141.00 price target on shares of Celgene Corp. in a research note on Monday, October 3rd. JPMorgan Chase & Co. restated an “overweight” rating and set a $136.00 price target on shares of Celgene Corp. in a research note on Friday, August 19th. Finally, Jefferies Group restated a “buy” rating and set a $134.00 price target on shares of Celgene Corp. in a research note on Monday, October 17th. Four analysts have rated the stock with a hold rating and twenty-seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $136.62.

In other news, Director Richard W. Barker sold 20,000 shares of the company’s stock in a transaction dated Friday, September 23rd. The shares were sold at an average price of $110.82, for a total transaction of $2,216,400.00. Following the transaction, the director now owns 31,332 shares in the company, valued at $3,472,212.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gilla Kaplan sold 9,710 shares of the company’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $106.44, for a total transaction of $1,033,532.40. Following the transaction, the director now owns 72,142 shares in the company, valued at approximately $7,678,794.48. The disclosure for this sale can be found here. Insiders own 0.97% of the company’s stock.

About Celgene Corp.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related stocks with our FREE daily email newsletter.